ObjectiveTo investigate the therapeutic effect of Shenkang injection combined with alprostadil injection on chronic nephritis and its effect on the level of inflammatory factors. MethodsA total of 120 patients with chronic nephritis admitted to our hospital from January to December 2018 were selected, and were divided into observation group and control group by random number table method, with 60 cases in each group. Patients in both groups were administered basic treatments including swelling and diuresis, blood pressure control, blood glucose control, as well as low-salt and low-protein diet, based on which patients in the control group were administered alprostadil injection, whereas patients in the observation group were administered alprostadil injection + Shenkang injection, for fourteen-day continuous treatment. The efficacy and the changes of inflammatory factor levels were compared between the two groups. ResultsThe total effective rate of treatment in the observation group was significantly higher than that in the control group (95.0% vs. 81.7%), with the statistically significant difference (P＜0.05). Before treatment, there were no significant differences in serum interleukin-18 (IL-18), tumor necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein (hs-CRP) levels between the two groups (P＞0.05). After 14 days of treatment, the serum IL-18, TNF-α, and hs-CRP levels of the two groups decreased significantly, and the levels in the observation group were significantly lower than those in the control group, with the statistically significant differences (P＜0.05). ConclusionOn the premise of basic treatment administration, employing Shenkang injection combined with alprostadil injection has a prominently clinical efficacy in patients with chronic nephritis, for it can obviously decrease the levels of inflammatory factors.

无